TY - JOUR

T1 - The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease

AU - Andreasen, Christine R.

AU - Andersen, Andreas

AU - Vilsbøll, Tina

N1 - Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2023

Y1 - 2023

N2 - In the last few decades, glucagon-like peptide-1 receptor (GLP-1R) agonists have changed current guidelines and improved outcomes for individuals with type 2 diabetes. However, the dual glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP-1R agonist, tirzepatide, has demonstrated superior efficacy regarding improvements in HbA1c and body weight in people with type 2 diabetes. This has led to increasing scientific interest in incretin hormones and incretin interactions, and several compounds based on dual- and multi-agonists are now being investigated for the treatment of metabolic diseases. Herein, we highlight the key scientific advances in utilising incretins for the treatment of obesity and, potentially, non-alcoholic fatty liver disease (NAFLD). The development of multi-agonists with multi-organ targets may alter the natural history of these diseases. Graphical Abstract: [Figure not available: see fulltext.].

AB - In the last few decades, glucagon-like peptide-1 receptor (GLP-1R) agonists have changed current guidelines and improved outcomes for individuals with type 2 diabetes. However, the dual glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP-1R agonist, tirzepatide, has demonstrated superior efficacy regarding improvements in HbA1c and body weight in people with type 2 diabetes. This has led to increasing scientific interest in incretin hormones and incretin interactions, and several compounds based on dual- and multi-agonists are now being investigated for the treatment of metabolic diseases. Herein, we highlight the key scientific advances in utilising incretins for the treatment of obesity and, potentially, non-alcoholic fatty liver disease (NAFLD). The development of multi-agonists with multi-organ targets may alter the natural history of these diseases. Graphical Abstract: [Figure not available: see fulltext.].

KW - Glucagon-like peptide-1

KW - Glucose-dependent insulinotropic polypeptide

KW - Incretins

KW - Non-alcoholic fatty liver disease

KW - Obesity

KW - Review

U2 - 10.1007/s00125-023-05966-9

DO - 10.1007/s00125-023-05966-9

M3 - Review

C2 - 37498367

AN - SCOPUS:85165901582

VL - 66

SP - 1846

EP - 1858

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

ER -